<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7367788\results\search\disease\results.xml">
  <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
  <result pre="as a global pandemic. Abstract The emergence of the severe" exact="acute" post="respiratory syndrome coronavirus-2 (SARS-CoV-2), responsible for causing coronavirus disease"/>
  <result pre="a global pandemic. Abstract The emergence of the severe acute" exact="respiratory" post="syndrome coronavirus-2 (SARS-CoV-2), responsible for causing coronavirus disease 2019"/>
  <result pre="global pandemic. Abstract The emergence of the severe acute respiratory" exact="syndrome" post="coronavirus-2 (SARS-CoV-2), responsible for causing coronavirus disease 2019 (COVID-19),"/>
  <result pre="severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), responsible for causing coronavirus" exact="disease" post="2019 (COVID-19), marked the third time in the twenty-first"/>
  <result pre="other parts of the world. This quick spread of SARS-CoV-2" exact="infection" post="to many states across the globe affecting many people"/>
  <result pre="prevent SARS-CoV-2 infection. The current therapeutic options for COVID-19 are" exact="limited" post="only to supportive measures and non-specific interventions. So, the"/>
  <result pre="are under trial for COVID-19. Also, possible mechanisms involved in" exact="viral" post="pathogenesis are discussed, which further allow us to understand"/>
  <result pre="drugs Pharmacological therapy A recent update Introduction The current Coronavirus" exact="Disease" post="2019 (COVID-19) has become a great threat to public"/>
  <result pre="coronavirus having more than 79% sequence homology with the severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) and 96% genome similarity with"/>
  <result pre="having more than 79% sequence homology with the severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) and 96% genome similarity with bat"/>
  <result pre="more than 79% sequence homology with the severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) and 96% genome similarity with bat coronavirus"/>
  <result pre="96% genome similarity with bat coronavirus [3], named as severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee"/>
  <result pre="genome similarity with bat coronavirus [3], named as severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on"/>
  <result pre="similarity with bat coronavirus [3], named as severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy"/>
  <result pre="its severity and rapid spread to many countries in a" exact="short" post="period, the World health organization (WHO) has declared this"/>
  <result pre="March 12, 2020 [5]. COVID-19 pandemic is a pandemic of" exact="respiratory" post="illness characterized by flu-like symptoms, sometimes associated with immune"/>
  <result pre="characterized by flu-like symptoms, sometimes associated with immune dysfunction and" exact="acute" post="respiratory distress syndrome (ARDS), which might lead to death"/>
  <result pre="by flu-like symptoms, sometimes associated with immune dysfunction and acute" exact="respiratory" post="distress syndrome (ARDS), which might lead to death [6]."/>
  <result pre="symptoms, sometimes associated with immune dysfunction and acute respiratory distress" exact="syndrome" post="(ARDS), which might lead to death [6]. It is"/>
  <result pre="is the third time in the twenty-first century, after severe" exact="acute" post="respiratory syndrome (SARS) in 2002 and 2003 and Middle"/>
  <result pre="the third time in the twenty-first century, after severe acute" exact="respiratory" post="syndrome (SARS) in 2002 and 2003 and Middle East"/>
  <result pre="third time in the twenty-first century, after severe acute respiratory" exact="syndrome" post="(SARS) in 2002 and 2003 and Middle East respiratory"/>
  <result pre="respiratory syndrome (SARS) in 2002 and 2003 and Middle East" exact="respiratory" post="syndrome (MERS) in 2012 when a highly pathogenic coronavirus"/>
  <result pre="syndrome (SARS) in 2002 and 2003 and Middle East respiratory" exact="syndrome" post="(MERS) in 2012 when a highly pathogenic coronavirus of"/>
  <result pre="the global economy. SARS-CoV-2 has a high potential to cause" exact="infection" post="with a higher transmission rate in comparison to SARS-CoV"/>
  <result pre="develop specific antiviral drugs for COVID-19, which would stop the" exact="viral" post="replication at the beginning and might reduce the associated"/>
  <result pre="immunologically directed strategies and anti-cytokine therapy is indispensable in SARS-CoV-2" exact="infection" post="as a notable proportion of COVID-19 patients have reported"/>
  <result pre="storm, which might damage the lungs and also lead to" exact="acute" post="respiratory distress syndrome (ARDS). In this regard, many drugs"/>
  <result pre="which might damage the lungs and also lead to acute" exact="respiratory" post="distress syndrome (ARDS). In this regard, many drugs previously"/>
  <result pre="damage the lungs and also lead to acute respiratory distress" exact="syndrome" post="(ARDS). In this regard, many drugs previously used to"/>
  <result pre="drugs previously used to treat SARS and MERS and other" exact="viral" post="diseases, including Ebola, HIV, and Influenza, have been evaluated"/>
  <result pre="and MERS-CoV, it has become the seventh coronavirus that causes" exact="infection" post="in human beings. The receptor-binding domain present in the"/>
  <result pre="protein undergoes conformational changes that help in the fusion of" exact="viral" post="and endosomal membranes. The viral RNA is then released"/>
  <result pre="help in the fusion of viral and endosomal membranes. The" exact="viral" post="RNA is then released into the host cell, and"/>
  <result pre="transmembrane protease serine-type 2 (TMPRSS2). After entering the cell, the" exact="viral" post="RNA gets uncoated and translated into viral polymerase protein."/>
  <result pre="the cell, the viral RNA gets uncoated and translated into" exact="viral" post="polymerase protein. After this, the viral RNA gets replicated"/>
  <result pre="uncoated and translated into viral polymerase protein. After this, the" exact="viral" post="RNA gets replicated using its RNA-dependent RNA polymerase (RdRp)."/>
  <result pre="viral RNA gets replicated using its RNA-dependent RNA polymerase (RdRp)." exact="Structural" post="proteins are then synthesized, assembled, and released outside the"/>
  <result pre="outside the cell [10]. The various steps involved in the" exact="viral" post="lifecycle provide potential targets for drug discovery and facilitates"/>
  <result pre="targets are 3-chymotrypsin-like protease (3CLPro) and papain-like protease (proteolysis of" exact="viral" post="polyprotein), RdRp (involved in viral replication), S protein (helps"/>
  <result pre="and papain-like protease (proteolysis of viral polyprotein), RdRp (involved in" exact="viral" post="replication), S protein (helps in viral entry by binding"/>
  <result pre="polyprotein), RdRp (involved in viral replication), S protein (helps in" exact="viral" post="entry by binding to ACE2), and TMPRSS2 (helps in"/>
  <result pre="COVID-19. ACE2 angiotensin converting enzyme 2, TMPRSS2 transmembrane protease serine" exact="type 2," post="RdRp RNA-dependent RNA polymerase, 3CLPro 3-chymotrypsin-like protease, ARDS acute"/>
  <result pre="type 2, RdRp RNA-dependent RNA polymerase, 3CLPro 3-chymotrypsin-like protease, ARDS" exact="acute" post="respiratory distress syndrome Pipeline Pharmacological Therapies for COVID-19 Research"/>
  <result pre="2, RdRp RNA-dependent RNA polymerase, 3CLPro 3-chymotrypsin-like protease, ARDS acute" exact="respiratory" post="distress syndrome Pipeline Pharmacological Therapies for COVID-19 Research for"/>
  <result pre="RNA-dependent RNA polymerase, 3CLPro 3-chymotrypsin-like protease, ARDS acute respiratory distress" exact="syndrome" post="Pipeline Pharmacological Therapies for COVID-19 Research for testing the"/>
  <result pre="biologics (monoclonal antibodies, interleukins, cytokines), ACE2 receptor blocker, angiotensin II" exact="type I" post="receptor blockers (ARB), fibrinolytic therapy, and combination therapy of"/>
  <result pre="been studied in clinical trials for COVID-19. To address the" exact="respiratory" post="distress associated with COVID-19, the role of drugs like"/>
  <result pre="various clinical trials. There is an emerging role of recombinant" exact="bacterial" post="ACE2 receptors like the enzyme of B38-CAP (rbACE2) for"/>
  <result pre="development of ARDS. It has been proposed that due to" exact="bacterial" post="origin, it might not get recognized by SARS-CoV-2 spike"/>
  <result pre="Targets and possible mechanism of action for use in COVID-19" exact="Disease" post="indication (Approved/Investigational)* Remdesivir (antiviral, adenosine nucleotide analog) Phase 2/3"/>
  <result pre="analog) Phase 2/3 Target RdRp and inhibit it, thereby inhibiting" exact="viral" post="replication and viral RNA synthesis Investigational drug for Ebola"/>
  <result pre="Target RdRp and inhibit it, thereby inhibiting viral replication and" exact="viral" post="RNA synthesis Investigational drug for Ebola virus and variety"/>
  <result pre="(antiviral, purine nucleoside analog) Phase 2/3/4 Target RdRp and inhibits" exact="viral" post="RNA synthesis Approved to treat influenza in Japan Ribavirin"/>
  <result pre="(antiviral, guanine nucleotide analog) Phase 1/2 Target RdRp and inhibits" exact="viral" post="RNA synthesis and mRNA capping Chronic hepatitis C virus"/>
  <result pre="Target RdRp and inhibits viral RNA synthesis and mRNA capping" exact="Chronic" post="hepatitis C virus (HCV) infection Galidesivir (antiviral, adenosine nucleoside"/>
  <result pre="RdRp and inhibits viral RNA synthesis and mRNA capping Chronic" exact="hepatitis C" post="virus (HCV) infection Galidesivir (antiviral, adenosine nucleoside analog) Phase"/>
  <result pre="RNA synthesis and mRNA capping Chronic hepatitis C virus (HCV)" exact="infection" post="Galidesivir (antiviral, adenosine nucleoside analog) Phase 1 Target and"/>
  <result pre="(antiviral, adenosine nucleoside analog) Phase 1 Target and bind to" exact="viral" post="RNA polymerase, premature termination of the elongating RNA strand"/>
  <result pre="the elongating RNA strand Investigational drug for Ebola, Marburg, Yellow" exact="Fever" post="and Zika viruses Lopinavir/Ritonavir (increases oral bioavailability of lopinavir)"/>
  <result pre="inhibits protein cleavage and halt virus maturation Approved for HIV-1" exact="infection" post="Darunavir (antiviral, protease inhibitor) and Cobicistat (Pharmacokinetic enhancer) Phase"/>
  <result pre="protease enzyme, inhibits protein cleavage and halt virus maturation (decrease" exact="viral" post="load and increase CD4 cell counts) Approved as second-"/>
  <result pre="CD4 cell counts) Approved as second- generation protease inhibitors for" exact="HIV infection" post="Umifenovir or Arbidol (antiviral, fusion inhibitor) Phase 4 Inhibits"/>
  <result pre="cell counts) Approved as second- generation protease inhibitors for HIV" exact="infection" post="Umifenovir or Arbidol (antiviral, fusion inhibitor) Phase 4 Inhibits"/>
  <result pre="or Arbidol (antiviral, fusion inhibitor) Phase 4 Inhibits fusion between" exact="viral" post="and cellular membrane Approved in Russia and China for"/>
  <result pre="arboviruses Danoprevir (antiviral, protease inhibitor) Phase 4 Target protease, Inhibits" exact="viral" post="replication Investigational drug for chronic hepatitis C patients Oseltamivir"/>
  <result pre="Phase 4 Target protease, Inhibits viral replication Investigational drug for" exact="chronic hepatitis C" post="patients Oseltamivir (antiviral, Neuraminidase inhibitor) Phase 2/3/4 Target neuraminidase"/>
  <result pre="4 Target protease, Inhibits viral replication Investigational drug for chronic" exact="hepatitis C" post="patients Oseltamivir (antiviral, Neuraminidase inhibitor) Phase 2/3/4 Target neuraminidase"/>
  <result pre="Oseltamivir (antiviral, Neuraminidase inhibitor) Phase 2/3/4 Target neuraminidase enzyme, inhibits" exact="viral" post="entry, replication and its release Approved for prophylaxis and"/>
  <result pre="Phase 2 Target TMPRSS2, inhibits its action and thereby inhibits" exact="viral" post="entry to cells Approved in Japan for chronic pancreatitis"/>
  <result pre="thereby inhibits viral entry to cells Approved in Japan for" exact="chronic" post="pancreatitis and drug-induced lung injury Clevudine (synthetic pyrimidine analog)"/>
  <result pre="inhibits viral entry to cells Approved in Japan for chronic" exact="pancreatitis" post="and drug-induced lung injury Clevudine (synthetic pyrimidine analog) Phase"/>
  <result pre="Phase 2 Target DNA polymerase and reverse transcriptase enzyme, block" exact="viral" post="replication and the supply of viral DNA into the"/>
  <result pre="reverse transcriptase enzyme, block viral replication and the supply of" exact="viral" post="DNA into the nucleus Investigational drug for hepatitis B"/>
  <result pre="supply of viral DNA into the nucleus Investigational drug for" exact="hepatitis" post="B Chloroquine and hydroxychloroquine (antimalarial, aminoquinolone derivative, antiviral and"/>
  <result pre="Changes the pH of endosomes and inhibit ACE2 glycosylation, prevent" exact="viral" post="entry, transport and, post-entry events Antimalarial drugs, also used"/>
  <result pre="entry, transport and, post-entry events Antimalarial drugs, also used for" exact="systemic" post="lupus erythematosus; acute and chronic rheumatoid arthritis Interferon-beta 1a"/>
  <result pre="transport and, post-entry events Antimalarial drugs, also used for systemic" exact="lupus erythematosus;" post="acute and chronic rheumatoid arthritis Interferon-beta 1a and 1b"/>
  <result pre="post-entry events Antimalarial drugs, also used for systemic lupus erythematosus;" exact="acute" post="and chronic rheumatoid arthritis Interferon-beta 1a and 1b (antiviral"/>
  <result pre="Antimalarial drugs, also used for systemic lupus erythematosus; acute and" exact="chronic" post="rheumatoid arthritis Interferon-beta 1a and 1b (antiviral and immunomodulators,"/>
  <result pre="drugs, also used for systemic lupus erythematosus; acute and chronic" exact="rheumatoid arthritis" post="Interferon-beta 1a and 1b (antiviral and immunomodulators, protein-based therapy)"/>
  <result pre="also used for systemic lupus erythematosus; acute and chronic rheumatoid" exact="arthritis" post="Interferon-beta 1a and 1b (antiviral and immunomodulators, protein-based therapy)"/>
  <result pre="protein-based therapy) Phase 2/4 (1a) Phase 2 (for 1b) Target" exact="type 1" post="interferon receptors, Activate JAK/STAT and stimulate innate antiviral immunity,"/>
  <result pre="changes the expression of cytokine and matrix metalloproteinase Relapsing remitting" exact="multiple sclerosis" post="(RRMS) Peginterferon lambda-1a (antiviral and immunomodulators, protein-based therapy) Phase"/>
  <result pre="2 Stimulate innate antiviral immunity Investigational long acting drug for" exact="hepatitis C" post="Convalescent plasma/hyperimmune plasma (passive Immunotherapy) Phase 1/2/3 Plasma from"/>
  <result pre="immunity to SARS-CoV-2 and can be used to reduce the" exact="viral" post="load and disease mortality in other patients Investigational approach"/>
  <result pre="and can be used to reduce the viral load and" exact="disease" post="mortality in other patients Investigational approach tried for emerging"/>
  <result pre="disease mortality in other patients Investigational approach tried for emerging" exact="Infectious" post="Diseases like Ebola virus Anakinra (recombinant interleukin, immunotherapy) Phase"/>
  <result pre="mortality in other patients Investigational approach tried for emerging Infectious" exact="Diseases" post="like Ebola virus Anakinra (recombinant interleukin, immunotherapy) Phase 2/3"/>
  <result pre="Ebola virus Anakinra (recombinant interleukin, immunotherapy) Phase 2/3 Target Interleukin-1" exact="type I" post="receptor (IL-1RI), and acts as an IL-1 receptor antagonist,"/>
  <result pre="acts as an IL-1 receptor antagonist, also block IL-18 production" exact="Rheumatoid arthritis" post="and neonatal-onset multisystem inflammatory disease Tocilizumab (recombinant humanized monoclonal"/>
  <result pre="as an IL-1 receptor antagonist, also block IL-18 production Rheumatoid" exact="arthritis" post="and neonatal-onset multisystem inflammatory disease Tocilizumab (recombinant humanized monoclonal"/>
  <result pre="IL-1 receptor antagonist, also block IL-18 production Rheumatoid arthritis and" exact="neonatal-onset multisystem inflammatory disease" post="Tocilizumab (recombinant humanized monoclonal antibody) Phase 2/3 IL-6 inhibitor,"/>
  <result pre="also block IL-18 production Rheumatoid arthritis and neonatal-onset multisystem inflammatory" exact="disease" post="Tocilizumab (recombinant humanized monoclonal antibody) Phase 2/3 IL-6 inhibitor,"/>
  <result pre="block cytokine storm Rheumatoid and giant cell arthritis, polyarticular and" exact="systemic" post="juvenile idiopathic arthritis, cytokine release syndrome Sarilumab (monoclonal antibody)"/>
  <result pre="cytokine storm Rheumatoid and giant cell arthritis, polyarticular and systemic" exact="juvenile idiopathic arthritis," post="cytokine release syndrome Sarilumab (monoclonal antibody) Phase 2/3 IL-6"/>
  <result pre="cell arthritis, polyarticular and systemic juvenile idiopathic arthritis, cytokine release" exact="syndrome" post="Sarilumab (monoclonal antibody) Phase 2/3 IL-6 inhibitor, blocks cytokine"/>
  <result pre="IL-6 inhibitor, blocks cytokine storm Moderate to severe reactive Rheumatoid" exact="Arthritis" post="Natural killer cells (biologicals) Phase 1/2 Innate lymphocytes that"/>
  <result pre="via the process of antibody-dependent cellular cytotoxicity, possess antiviral effect" exact="Cancer" post="immunotherapy Stem cell therapy (biologicals) Phase 2 Mesenchymal stem"/>
  <result pre="antiviral effect Cancer immunotherapy Stem cell therapy (biologicals) Phase 2" exact="Mesenchymal" post="stem cells (MSCs) have high regenerative and immunomodulatory capacities."/>
  <result pre="enhance pathogen clearance, and reduce the severity of the injury," exact="pulmonary" post="dysfunction, and apoptosis. Several carcinomas, inherited metabolic disorders, myelodysplastic"/>
  <result pre="injury, pulmonary dysfunction, and apoptosis. Several carcinomas, inherited metabolic disorders," exact="myelodysplastic syndromes," post="lymphomas, leukemias, other disorders of blood cell proliferation, inherited"/>
  <result pre="Sphingosine-1-phosphate receptor and acts as a functional antagonist and reduces" exact="lung inflammation" post="Relapsing remitting multiple sclerosis (RRMS) Bevacizumab (recombinant humanized monoclonal"/>
  <result pre="as a functional antagonist and reduces lung inflammation Relapsing remitting" exact="multiple sclerosis" post="(RRMS) Bevacizumab (recombinant humanized monoclonal antibody, VEGF inhibitor) Phase"/>
  <result pre="Bevacizumab (recombinant humanized monoclonal antibody, VEGF inhibitor) Phase 3 Target" exact="vascular" post="endothelial growth factor (VEGF), inhibit it and prevents acute"/>
  <result pre="Target vascular endothelial growth factor (VEGF), inhibit it and prevents" exact="acute" post="lung injury (ALI) and ARDS Metastatic colorectal cancer, metastatic"/>
  <result pre="it and prevents acute lung injury (ALI) and ARDS Metastatic" exact="colorectal cancer," post="metastatic and recurrent non-squamous non-small cell lung cancer, metastatic"/>
  <result pre="prevents acute lung injury (ALI) and ARDS Metastatic colorectal cancer," exact="metastatic" post="and recurrent non-squamous non-small cell lung cancer, metastatic renal"/>
  <result pre="lung injury (ALI) and ARDS Metastatic colorectal cancer, metastatic and" exact="recurrent" post="non-squamous non-small cell lung cancer, metastatic renal cell carcinoma,"/>
  <result pre="ARDS Metastatic colorectal cancer, metastatic and recurrent non-squamous non-small cell" exact="lung cancer," post="metastatic renal cell carcinoma, recurrent cervical cancer, epithelial ovarian"/>
  <result pre="colorectal cancer, metastatic and recurrent non-squamous non-small cell lung cancer," exact="metastatic" post="renal cell carcinoma, recurrent cervical cancer, epithelial ovarian cancer"/>
  <result pre="cancer, metastatic and recurrent non-squamous non-small cell lung cancer, metastatic" exact="renal cell carcinoma," post="recurrent cervical cancer, epithelial ovarian cancer etc. Baricitinib (kinase"/>
  <result pre="recurrent non-squamous non-small cell lung cancer, metastatic renal cell carcinoma," exact="recurrent" post="cervical cancer, epithelial ovarian cancer etc. Baricitinib (kinase inhibitor)"/>
  <result pre="non-squamous non-small cell lung cancer, metastatic renal cell carcinoma, recurrent" exact="cervical cancer," post="epithelial ovarian cancer etc. Baricitinib (kinase inhibitor) Phase 2/3"/>
  <result pre="cell lung cancer, metastatic renal cell carcinoma, recurrent cervical cancer," exact="epithelial" post="ovarian cancer etc. Baricitinib (kinase inhibitor) Phase 2/3 Target"/>
  <result pre="lung cancer, metastatic renal cell carcinoma, recurrent cervical cancer, epithelial" exact="ovarian cancer" post="etc. Baricitinib (kinase inhibitor) Phase 2/3 Target JAK kinase"/>
  <result pre="cancer, metastatic renal cell carcinoma, recurrent cervical cancer, epithelial ovarian" exact="cancer" post="etc. Baricitinib (kinase inhibitor) Phase 2/3 Target JAK kinase"/>
  <result pre="inhibits the down-streaming signaling cascades of cytokines and growth factors" exact="Rheumatoid arthritis" post="in adult patients Ruxolitinib (kinase inhibitor) Phase 1/2/3 Target"/>
  <result pre="the down-streaming signaling cascades of cytokines and growth factors Rheumatoid" exact="arthritis" post="in adult patients Ruxolitinib (kinase inhibitor) Phase 1/2/3 Target"/>
  <result pre="signaling cascades of cytokines and growth factors Rheumatoid arthritis in" exact="adult" post="patients Ruxolitinib (kinase inhibitor) Phase 1/2/3 Target JAK kinase"/>
  <result pre="signaling cascades of cytokines and growth factors Intermediate or high-risk" exact="myelofibrosis" post="Acalabrutinib (kinase inhibitor) Phase 2 A selective inhibitor of"/>
  <result pre="and inhibits downstream B-cell antigen receptor and cytokine receptor pathways" exact="Chronic" post="lymphocytic leukemia or small lymphocytic lymphoma CD24Fc (biological immunomodulatory,"/>
  <result pre="inhibits downstream B-cell antigen receptor and cytokine receptor pathways Chronic" exact="lymphocytic leukemia" post="or small lymphocytic lymphoma CD24Fc (biological immunomodulatory, comprises the"/>
  <result pre="downstream B-cell antigen receptor and cytokine receptor pathways Chronic lymphocytic" exact="leukemia" post="or small lymphocytic lymphoma CD24Fc (biological immunomodulatory, comprises the"/>
  <result pre="antigen receptor and cytokine receptor pathways Chronic lymphocytic leukemia or" exact="small lymphocytic lymphoma" post="CD24Fc (biological immunomodulatory, comprises the nonpolymorphic regions of CD24"/>
  <result pre="and cytokine receptor pathways Chronic lymphocytic leukemia or small lymphocytic" exact="lymphoma" post="CD24Fc (biological immunomodulatory, comprises the nonpolymorphic regions of CD24"/>
  <result pre="death and regulate cytokine production Adjuvant for influenza vaccine and" exact="hepatitis" post="B vaccines Tradipitant (neurokinin-1 (NK1) receptor antagonist) Phase 3"/>
  <result pre="by blocking substance P, reduces inflammatory lung injury and relieves" exact="chronic" post="cough An investigational drug in trials of eczema, pruritus,"/>
  <result pre="cough An investigational drug in trials of eczema, pruritus, gastroparesis," exact="chronic" post="pruritus, atopic dermatitis Eculizumab (monoclonal antibody, terminal complement inhibitor)"/>
  <result pre="investigational drug in trials of eczema, pruritus, gastroparesis, chronic pruritus," exact="atopic dermatitis" post="Eculizumab (monoclonal antibody, terminal complement inhibitor) Phase 2 Target"/>
  <result pre="drug in trials of eczema, pruritus, gastroparesis, chronic pruritus, atopic" exact="dermatitis" post="Eculizumab (monoclonal antibody, terminal complement inhibitor) Phase 2 Target"/>
  <result pre="prevents activation of a complement terminal complex and immune-mediated inflammation" exact="Paroxysmal nocturnal hemoglobinuria" post="Sargramostim (recombinant humanized granulocyte-macrophage colony stimulating factor (rhuGM-CSF)) Phase"/>
  <result pre="activation of a complement terminal complex and immune-mediated inflammation Paroxysmal" exact="nocturnal" post="hemoglobinuria Sargramostim (recombinant humanized granulocyte-macrophage colony stimulating factor (rhuGM-CSF))"/>
  <result pre="of a complement terminal complex and immune-mediated inflammation Paroxysmal nocturnal" exact="hemoglobinuria" post="Sargramostim (recombinant humanized granulocyte-macrophage colony stimulating factor (rhuGM-CSF)) Phase"/>
  <result pre="signal transduction pathway, pivotal function in hematopoiesis and cell-mediated immunity." exact="Cancer" post="and bone marrow transplant Aviptadil (vasoactive intestinal polypeptide) Phase"/>
  <result pre="barrier function at the endothelial/alveolar interface Approved in Europe for," exact="erectile dysfunction," post="FDA orphan drug designation for treating ARDS Telmisartan, Losartan"/>
  <result pre="2/3/4 (one phase 1 study for losartan) Target angiotensin II" exact="type 1" post="(AT1) receptors, degrade angiotensin II to angiotensin 1â€&quot;7, reduces"/>
  <result pre="release of proinflammatory cytokines thereby reduces chances of ARDS Hypertension;" exact="diabetic nephropathy" post="in hypertensive patients with type 2 diabetes mellitus; congestive"/>
  <result pre="of proinflammatory cytokines thereby reduces chances of ARDS Hypertension; diabetic" exact="nephropathy" post="in hypertensive patients with type 2 diabetes mellitus; congestive"/>
  <result pre="chances of ARDS Hypertension; diabetic nephropathy in hypertensive patients with" exact="type 2" post="diabetes mellitus; congestive heart failure Isotretinoin (retinoid derivative of"/>
  <result pre="ARDS Hypertension; diabetic nephropathy in hypertensive patients with type 2" exact="diabetes mellitus;" post="congestive heart failure Isotretinoin (retinoid derivative of vitamin A)"/>
  <result pre="diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus;" exact="congestive heart failure" post="Isotretinoin (retinoid derivative of vitamin A) Phase 1/3 Strongest"/>
  <result pre="nephropathy in hypertensive patients with type 2 diabetes mellitus; congestive" exact="heart" post="failure Isotretinoin (retinoid derivative of vitamin A) Phase 1/3"/>
  <result pre="protease (PLpro), which is a protein encoded by SARS-CoV-2 genes" exact="Severe" post="recalcitrant nodular acne Naproxen (anti-inflammatory) (studied in combination with"/>
  <result pre="which is a protein encoded by SARS-CoV-2 genes Severe recalcitrant" exact="nodular" post="acne Naproxen (anti-inflammatory) (studied in combination with antiviral) Phase"/>
  <result pre="is a protein encoded by SARS-CoV-2 genes Severe recalcitrant nodular" exact="acne" post="Naproxen (anti-inflammatory) (studied in combination with antiviral) Phase 3"/>
  <result pre="(COX-2) and Influenza A virus nucleoprotein (NP), reduces inflammation Osteoarthritis," exact="rheumatoid arthritis," post="acute gouty arthritis, primary dysmenorrhea, for inflammation and pain"/>
  <result pre="Influenza A virus nucleoprotein (NP), reduces inflammation Osteoarthritis, rheumatoid arthritis," exact="acute" post="gouty arthritis, primary dysmenorrhea, for inflammation and pain in"/>
  <result pre="nucleoprotein (NP), reduces inflammation Osteoarthritis, rheumatoid arthritis, acute gouty arthritis," exact="primary" post="dysmenorrhea, for inflammation and pain in musculoskeletal Azithromycin (broad-spectrum"/>
  <result pre="in combination with hydroxychloroquine or amoxicillin/clavulanic acid)) Phase 2/3/4 Target" exact="bacterial" post="ribosomes, inhibits transpeptidation and stops protein synthesis, also have"/>
  <result pre="stops protein synthesis, also have immunomodulatory effects, which might decrease" exact="respiratory" post="inflammation Respiratory, enteric and genitourinary infections; some sexually transmitted"/>
  <result pre="enteric and genitourinary infections; some sexually transmitted and enteric infections," exact="infections" post="caused by susceptible strains of the microorganisms listed by"/>
  <result pre="in combination with hydroxychloroquine, or other drugs) Phase 2/3 Targets" exact="viral" post="hemagglutinin and the viral transcription factor, inhibits viral replication,"/>
  <result pre="or other drugs) Phase 2/3 Targets viral hemagglutinin and the" exact="viral" post="transcription factor, inhibits viral replication, possess anti-cytokine and autophagy"/>
  <result pre="2/3 Targets viral hemagglutinin and the viral transcription factor, inhibits" exact="viral" post="replication, possess anti-cytokine and autophagy properties diarrhea in adults"/>
  <result pre="transcription factor, inhibits viral replication, possess anti-cytokine and autophagy properties" exact="diarrhea" post="in adults and children Colchicine (alkaloids, anti-inflammatory drug) Phase"/>
  <result pre="production of IL-1Î² and IL-6, prevents cytokine storm Gout and" exact="familial" post="Mediterranean fever Deferoxamine (iron chelator) Phase 1/2/3 Manages excess"/>
  <result pre="of IL-1Î² and IL-6, prevents cytokine storm Gout and familial" exact="Mediterranean fever" post="Deferoxamine (iron chelator) Phase 1/2/3 Manages excess iron levels"/>
  <result pre="in the blood, prevents iron toxicity and hence prevents severe" exact="respiratory" post="manifestations and inflammation in the alveoli Acute iron or"/>
  <result pre="hence prevents severe respiratory manifestations and inflammation in the alveoli" exact="Acute" post="iron or aluminum toxicity; anemia in patients who must"/>
  <result pre="and inflammation in the alveoli Acute iron or aluminum toxicity;" exact="anemia" post="in patients who must receive many blood transfusions Heparin"/>
  <result pre="and thrombin by binding to the plasma protease inhibitor, prevents" exact="venous thromboembolism" post="in COVID-19 patients Prevention of postoperative venous thromboembolism; deep"/>
  <result pre="inhibitor, prevents venous thromboembolism in COVID-19 patients Prevention of postoperative" exact="venous thromboembolism;" post="deep vein thrombosis and/or pulmonary embolism; prevention of clot"/>
  <result pre="venous thromboembolism in COVID-19 patients Prevention of postoperative venous thromboembolism;" exact="deep vein thrombosis" post="and/or pulmonary embolism; prevention of clot formation in indwelling"/>
  <result pre="in COVID-19 patients Prevention of postoperative venous thromboembolism; deep vein" exact="thrombosis" post="and/or pulmonary embolism; prevention of clot formation in indwelling"/>
  <result pre="patients Prevention of postoperative venous thromboembolism; deep vein thrombosis and/or" exact="pulmonary embolism;" post="prevention of clot formation in indwelling intravenous lines for"/>
  <result pre="oxide (INO) (pulmonary vasodilator) Phase 1/2 Targets heme molecule of" exact="cytosolic" post="guanylate cyclase and results in pulmonary vasodilation, early administration"/>
  <result pre="Targets heme molecule of cytosolic guanylate cyclase and results in" exact="pulmonary" post="vasodilation, early administration might prevent cases of respiratory failure"/>
  <result pre="results in pulmonary vasodilation, early administration might prevent cases of" exact="respiratory" post="failure in COVID-19, also act as anti-thrombotic in lung"/>
  <result pre="failure in COVID-19, also act as anti-thrombotic in lung Hypoxic" exact="respiratory" post="failure in neonates Ascorbic acid (nutraceutical, antioxidant) Phase 1/2/3"/>
  <result pre="reduce the risk of development of inflammatory markers, ARDS and" exact="respiratory" post="failure Approved for scurvy, delayed wound and bone healing,"/>
  <result pre="wound and bone healing, urine acidification. Investigational drug for sepsis," exact="acute" post="lung injury (ALI) *All drugs mentioned here are investigational"/>
  <result pre="for COVID-19; however, they might be approved for some other" exact="disease" post="indications Table 2 List of natural products under clinical"/>
  <result pre="Phase 3 Immunomodulator, antibacterial, and antiviral Artemisinin, Curcumin, Boswellia, and" exact="Vitamin C" post="(ArtemiC) Phase 2 Anti-oxidant, anti-inflammatory, and anti-aggregant and anti-microbial"/>
  <result pre="cytokines such as TNF-Î±, IL-1Î², IL-6, IL-8, and IL-10, inhibit" exact="lung inflammation" post="or acute lung injury Promising Drugs for COVID-19: Current"/>
  <result pre="TNF-Î±, IL-1Î², IL-6, IL-8, and IL-10, inhibit lung inflammation or" exact="acute" post="lung injury Promising Drugs for COVID-19: Current Status and"/>
  <result pre="a phase 3 study for the treatment of EBOLA virus" exact="disease" post="[17]. Currently, remdesivir is one of the most promising"/>
  <result pre="of COVID-19. It acts as an RdRp inhibitor and blocks" exact="viral" post="RNA replication [18]. It has shown its therapeutic potential"/>
  <result pre="remdesivir group were constipation, hypoalbuminemia, hypokalemia, anemia, thrombocytopenia, and increased" exact="total" post="bilirubin. Moreover, the preliminary report of a double-blind, randomized,"/>
  <result pre="limitation of this study was the open-label design and the" exact="absence of" post="a placebo control group [25]. However, whether remdesivir is"/>
  <result pre="(favipiravir-RTP) and acts by inhibiting RNA polymerase activity, thus ceasing" exact="viral" post="replication [27]. It has been approved in Japan and"/>
  <result pre="has stated the more potent antiviral action (shorter time for" exact="viral" post="clearance) of favipiravir plus interferon-alpha than that of lopinavir/ritonavir"/>
  <result pre="favipiravir has shown a variable range of IC50 in various" exact="viral" post="studies, [27] and some studies have documented a possible"/>
  <result pre="and Ritonavir These protease inhibitors are widely used for human" exact="immunodeficiency" post="virus (HIV) and have also shown potential antiviral activity"/>
  <result pre="and act by inhibiting the 3CLPro enzyme and thereby stop" exact="viral" post="protein synthesis [33]. Lopinavir has shown efficacy against the"/>
  <result pre="increasing the pH of endosomes and prevent the fusion of" exact="viral" post="and host cell membrane [38]. They also interfere with"/>
  <result pre="beneficial role of CQ phosphate in reducing the severity of" exact="pneumonia" post="and lung injury, thereby decreasing the course of the"/>
  <result pre="pneumonia and lung injury, thereby decreasing the course of the" exact="disease" post="in almost 100 patients of COVID-19 in comparison to"/>
  <result pre="HCQ group and 16 in the control group) reported improved" exact="viral" post="clearance with HCQ compared with control group patients receiving"/>
  <result pre="the treatment of 6 patients has shown more improvements in" exact="viral" post="clearance in comparison to the HCQ alone group [40]."/>
  <result pre="India, HCQ is used as a prophylactic drug for SARS-CoV-2" exact="infection" post="in healthcare professionals. Recently, the results of a most"/>
  <result pre="events were reported with the CQ and HCQ group including" exact="arrhythmia" post="and the survival rates were also less in these"/>
  <result pre="SARS-CoV-2 and can be used to reduce the viremia and" exact="disease" post="mortality in patients with life-threatening SARS-CoV-2 infections. Convalescent plasma"/>
  <result pre="plasma therapy has been used in the past for many" exact="viral" post="infections such as Ebola, influenza, poliomyelitis, SARS, and MERS"/>
  <result pre="therapy has been used in the past for many viral" exact="infections" post="such as Ebola, influenza, poliomyelitis, SARS, and MERS and"/>
  <result pre="demonstrated the improvement in clinical symptoms including a reduction in" exact="viral" post="load [50]. Also, improvement in clinical outcomes was seen"/>
  <result pre="of neutralizing monoclonal antibodies [52]. Moreover, cytokine storm (CS), i.e.," exact="uncontrolled" post="release of pro-inflammatory cytokines has been reported to correlate"/>
  <result pre="release of pro-inflammatory cytokines has been reported to correlate with" exact="disease" post="severity in SARS-CoV-2 infection, and it might lead to"/>
  <result pre="disease severity in SARS-CoV-2 infection, and it might lead to" exact="acute" post="lung injury, acute respiratory distress syndrome (ARDS), and death"/>
  <result pre="SARS-CoV-2 infection, and it might lead to acute lung injury," exact="acute" post="respiratory distress syndrome (ARDS), and death [53, 54]. Several"/>
  <result pre="infection, and it might lead to acute lung injury, acute" exact="respiratory" post="distress syndrome (ARDS), and death [53, 54]. Several reports"/>
  <result pre="it might lead to acute lung injury, acute respiratory distress" exact="syndrome" post="(ARDS), and death [53, 54]. Several reports have confirmed"/>
  <result pre="COVID-19 pathogenesis. These recombinant human monoclonal antibodies are indicated for" exact="rheumatoid arthritis" post="(RA). Till now, several clinical trials of tocilizumab and"/>
  <result pre="pathogenesis. These recombinant human monoclonal antibodies are indicated for rheumatoid" exact="arthritis" post="(RA). Till now, several clinical trials of tocilizumab and"/>
  <result pre="drugs, have been registered in patients with COVID-19 with severe" exact="pneumonia" post="[13]. In a retrospective study in China, the administration"/>
  <result pre="COVID-19 has shown improvement in clinical outcomes such as improved" exact="respiratory" post="function in 91% of patients [59]. Also, sarilumab is"/>
  <result pre="of tocilizumab in COVID-19 patients. Cell-Based Therapies (NK Cells and" exact="Mesenchymal" post="Stem Cells) Cell-based therapies have now been proposed as"/>
  <result pre="cells (CYNK-001), which is used earlier in small numbers of" exact="cancer" post="patients and found safe. CYNK-001 is a cryopreserved allogeneic"/>
  <result pre="reported that NK cells can exert antiviral activity against SARS," exact="herpes" post="simplex virus type 1 (HSV-1), cytomegalovirus (CMV), and HIV"/>
  <result pre="cells can exert antiviral activity against SARS, herpes simplex virus" exact="type 1" post="(HSV-1), cytomegalovirus (CMV), and HIV [61â€&quot;63]. As the number"/>
  <result pre="in COVID-19 patients and hence prevents the progression of the" exact="disease" post="and reduces mortality. However, more clinical trials with a"/>
  <result pre="Chinese medicines (TCM) in the treatment or prevention of many" exact="viral" post="infections including influenza, SARS, and MERS, the application of"/>
  <result pre="medicines (TCM) in the treatment or prevention of many viral" exact="infections" post="including influenza, SARS, and MERS, the application of TCM"/>
  <result pre="Forsythiae), thereby decreasing the severity and mortality rate of the" exact="disease" post="[69]. In a molecular docking study by Chen and"/>
  <result pre="ACE2 receptor and exerting an antiviral effect to prevent SARS-CoV-2" exact="infection" post="[70]. Medical institutions in China have published many TCM"/>
  <result pre="many TCM prescriptions, and guideline in China (The Novel Coronavirus" exact="Pneumonia" post="Diagnosis and Treatment Plan, 6th trial version) has also"/>
  <result pre="boost the immunity and have shown the efficacy against many" exact="viral" post="infections, including influenza virus, HIV, and SARS-CoV [72, 73]."/>
  <result pre="exhibited several antiviral mechanisms against SARS-CoV, such as inhibiting the" exact="viral" post="3CL protease and blocking the viral RNA-dependent RNA polymerase"/>
  <result pre="such as inhibiting the viral 3CL protease and blocking the" exact="viral" post="RNA-dependent RNA polymerase activity thereby preventing the early stage"/>
  <result pre="polymerase activity thereby preventing the early stage of infection, including" exact="viral" post="attachment and penetration [72, 74]. Several drugs such as"/>
  <result pre="targeted and efficacious treatment for COVID-19; however, certain barriers have" exact="limited" post="the results of previous trials, and these need to"/>
  <result pre="traditional drug discovery process, so that this can reduce the" exact="total" post="time taken and could be helpful in faster development"/>
  <result pre="for a broad-spectrum antiviral agent that could effectively reduce the" exact="viral" post="load targeting a wide group of viruses and helps"/>
  <result pre="symptoms like lymphocytopenia and cytokine storm that might lead to" exact="acute" post="lung injury and respiratory failure. Also, emphasis should be"/>
  <result pre="cytokine storm that might lead to acute lung injury and" exact="respiratory" post="failure. Also, emphasis should be given to the rational"/>
  <result pre="Coronavirus Investigating and Research TeamA novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N Engl J Med202038272773331978945 2.World Health Organisation."/>
  <result pre="China, 2019N Engl J Med202038272773331978945 2.World Health Organisation. WHO Coronavirus" exact="Disease" post="(COVID-19) Dashboard [Internet]. Available from: https://covid19.who.int/. Accessed 4th July"/>
  <result pre="Available from: https://covid19.who.int/. Accessed 4th July 2020. 2020. 3.ZhouPLouYXWangXGHuBZhangLZhangWet al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="coronavirus of probable bat originNature202057927027332015507 4.GorbalenyaAEBakerSCBaricRSde GrootRJDrostenCGulyaevaAAet al.The species severe" exact="acute" post="respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nat"/>
  <result pre="of probable bat originNature202057927027332015507 4.GorbalenyaAEBakerSCBaricRSde GrootRJDrostenCGulyaevaAAet al.The species severe acute" exact="respiratory" post="syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nat Microbiol2020553654432123347"/>
  <result pre="anti-inflammatory drugs in the treatment of people with severe coronavirus" exact="disease" post="2019 (COVID-19): the experience of clinical immunologists from ChinaClin"/>
  <result pre="WerfSBrodtHRBeckerSet al.Identification of a novel coronavirus in patients with severe" exact="acute" post="respiratory syndromeN Engl J Med20033481967197612690091 8.ZakiAMVan BoheemenSBestebroerTMOsterhausADMEFouchierRAMIsolation of a"/>
  <result pre="al.Identification of a novel coronavirus in patients with severe acute" exact="respiratory" post="syndromeN Engl J Med20033481967197612690091 8.ZakiAMVan BoheemenSBestebroerTMOsterhausADMEFouchierRAMIsolation of a novel"/>
  <result pre="8.ZakiAMVan BoheemenSBestebroerTMOsterhausADMEFouchierRAMIsolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN Engl J Med20123671814182023075143 9.ChanJFWKokKHZhuZChuHcollab: To KKWYuanSet"/>
  <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical pneumonia" post="after visiting WuhanEmerg Microbes Infect2020922123631987001 10.JiangSHillyerCDuLNeutralizing antibodies against SARS-CoV-2"/>
  <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerg Microbes Infect2020922123631987001 10.JiangSHillyerCDuLNeutralizing antibodies against SARS-CoV-2"/>
  <result pre="Acad Sci20201176771677632054787 17.ProschanMPhDMukadiDManzoMLPhDNzoloDet al.A randomized, controlled trial of Ebola virus" exact="disease" post="therapeutics SabueN Engl J Med20193812293230331774950 18.BrownAJWonJJGrahamRLDinnonKHSimsACFengJYet al.Broad spectrum antiviral"/>
  <result pre="RNA viruses. 2020;3â€&quot;5. 27.FurutaYFavipiravir (T-705), a broad spectrum inhibitor of" exact="viral" post="RNA polymeraseProc Jpn Acad201793449463 28.Cai Q, Yang M, Liu"/>
  <result pre="FDA-approved compound library identifies four small-molecule inhibitors of Middle East" exact="respiratory" post="syndrome coronavirus replication in cell cultureAntimicrob Agents Chemother2014584875488424841269 34.CaoBWangYWenDLiuWWangJFanGRuanLSongBCaiYWeiMLiXXiaJChenNXiangJYuTBaiTXieXZhangLLiCYuanYChenHLiHHuangHTuSGongFLiuYWeiYDongCZhouFGuXXuJLiuZZhangYLiHShangLWangKLiKZhouXDongXQuZLuSHuXRuanSLuoSWuJPengLChengFPanLZouJJiaCWangJLiuXWangSWuXGeQHeJZhanHQiuFGuoLHuangCJakiTHaydenFGHorbyPWZhangDWangCA"/>
  <result pre="compound library identifies four small-molecule inhibitors of Middle East respiratory" exact="syndrome" post="coronavirus replication in cell cultureAntimicrob Agents Chemother2014584875488424841269 34.CaoBWangYWenDLiuWWangJFanGRuanLSongBCaiYWeiMLiXXiaJChenNXiangJYuTBaiTXieXZhangLLiCYuanYChenHLiHHuangHTuSGongFLiuYWeiYDongCZhouFGuXXuJLiuZZhangYLiHShangLWangKLiKZhouXDongXQuZLuSHuXRuanSLuoSWuJPengLChengFPanLZouJJiaCWangJLiuXWangSWuXGeQHeJZhanHQiuFGuoLHuangCJakiTHaydenFGHorbyPWZhangDWangCA trial"/>
  <result pre="Infect Dis20066676916439323 37.YanYZouZSunYLiXXuKFWeiYJinNJiangCAnti-malaria drug chloroquine is highly effective in treating" exact="avian influenza" post="A H5N1 virus infection in an animal modelCell Res20132330030223208422"/>
  <result pre="chloroquine is highly effective in treating avian influenza A H5N1" exact="virus infection" post="in an animal modelCell Res20132330030223208422 38.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.Chloroquine is a"/>
  <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal modelCell Res20132330030223208422 38.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.Chloroquine is a"/>
  <result pre="Res20132330030223208422 38.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J2005211015631631 39.GaoJTianZYangXBreakthrough: Chloroquine phosphate has shown apparent"/>
  <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci Trends202014727332074550 40.Gautret P, Lagier JC, Parola"/>
  <result pre="different dosages as adjunctive therapy of hospitalized patients with severe" exact="respiratory" post="syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary"/>
  <result pre="dosages as adjunctive therapy of hospitalized patients with severe respiratory" exact="syndrome" post="in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety"/>
  <result pre="48.Van GriensvenJEdwardsTDe LamballerieXSempleMGGallianPBaizeSet al.Evaluation of convalescent plasma for Ebola virus" exact="disease" post="in GuineaN Engl J Med2016374334226735992 49.RinaldoCRPassive immunization against poliomyelitis:"/>
  <result pre="of cytokine storm and immunopathologySemin Immunopathol20173952953928466096 54.ChoustermanBGSwirskiFKWGCytokine storm and sepsis" exact="disease" post="pathogenesisSemin Immunopathol20173951752828555385 55.Ruan Q, Yang K, Wang W, Jiang"/>
  <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet.202039550751332007143 57.Wu C, Chen"/>
  <result pre="Zhou X, Xu S, et al. Risk factors associated with" exact="acute" post="respiratory distress syndrome and death in patients with coronavirus"/>
  <result pre="X, Xu S, et al. Risk factors associated with acute" exact="respiratory" post="distress syndrome and death in patients with coronavirus disease"/>
  <result pre="S, et al. Risk factors associated with acute respiratory distress" exact="syndrome" post="and death in patients with coronavirus disease 2019 pneumonia"/>
  <result pre="acute respiratory distress syndrome and death in patients with coronavirus" exact="disease" post="2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020:1â€&quot;24."/>
  <result pre="distress syndrome and death in patients with coronavirus disease 2019" exact="pneumonia" post="in Wuhan, China. JAMA Intern Med. 2020:1â€&quot;24. 58.Liu T,"/>
  <result pre="et al. The potential role of IL-6 in monitoring coronavirus" exact="disease" post="2019. medRxiv. 2020;10.1101/2020.03.01.20029769. 59.Xu X, Han M, Li T,"/>
  <result pre="patients with tocilizumab. chinaXiv. 2020;. 60.HammerQRÃ¼ckertTRomagnaniCNatural killer cell specificity for" exact="viral" post="infectionsNat Immunol20181980080830026479 61.DaiHSCaligiuriMAMolecular basis for the recognition of Herpes"/>
  <result pre="Immunol20181980080830026479 61.DaiHSCaligiuriMAMolecular basis for the recognition of Herpes simplex virus" exact="type 1" post="infection by human natural killer cellsFront Immunol201891829403488 62.AraseHMocarskiESCampbellAEHillABLanierLLDirect recognition"/>
  <result pre="basis for the recognition of Herpes simplex virus type 1" exact="infection" post="by human natural killer cellsFront Immunol201891829403488 62.AraseHMocarskiESCampbellAEHillABLanierLLDirect recognition of"/>
  <result pre="involvement of natural killer cells in the pathogenesis of severe" exact="acute" post="respiratory syndromeAm J Clin Pathol200412150751115080302 64.MoodleyYAtienzaDManuelpillaiUSamuelCSTchongueJIlancheranSBoydRTrounsonAHuman umbilical cord mesenchymal"/>
  <result pre="of natural killer cells in the pathogenesis of severe acute" exact="respiratory" post="syndromeAm J Clin Pathol200412150751115080302 64.MoodleyYAtienzaDManuelpillaiUSamuelCSTchongueJIlancheranSBoydRTrounsonAHuman umbilical cord mesenchymal stem"/>
  <result pre="bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced" exact="acute" post="lung injury in miceJ Immunol20071791855186317641052 67.Zumla A, Wang F,"/>
  <result pre="al. Reducing mortality and morbidity in patients with severe COVID-19" exact="disease" post="by advancing ongoing trials of Mesenchymal Stromal (stem) Cell"/>
  <result pre="patients with severe COVID-19 disease by advancing ongoing trials of" exact="Mesenchymal" post="Stromal (stem) Cell (MSC) therapy â€&quot; Achieving global consensus"/>
  <result pre="al.Can Chinese medicine be used for prevention of corona virus" exact="disease" post="2019 (COVID-19)? A review of historical classics, Research Evidence"/>
  <result pre="Ayurveda and COVID-19: where psychoneuroimmunology and the meaning response meet." exact="Brain" post="Behav Immun. Elsevier; 2020;87:8â€&quot;9. Available from: 10.1016/j.bbi.2020.04.056 76.BalasubramaniSPVenkatasubramanianPKukkupuniSKPatwardhanBPlant-based Rasayana"/>
 </snippets>
</snippetsTree>
